

IOL CHEMICALS AND PHARMACEUTICALS LIMITED

IOL CHEMICALS AND PHARMACEUTICALS LTD UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31 DECEMBER 2015

Rs. in Lacs

| Sr. | | Particulars | | Overden Francis | <u> </u> | N: 85 | 4b - F- J- J | Rs. in Lacs |
|----------|----------|---|-------------|-----------------|--------------|-------------|--------------------------|--------------------|
| | | Particulars | | Quarter Ended | | | ths Ended | Year ended |
| No. | | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | | (Audited) |
| | Ц | | 31.12.2015 | 30.09.2015 | 31.12.2014 | 31.12.2015 | 31.12.2014 | 31.03.2015 |
| | Н | | | | | | ļ | |
| 1 | Ы | Income from Operations | | | | | | |
| | а | Net Sales / Income from operations (net of excise duty) | 14314.71 | 15814.19 | 6779.49 | 43823.32 | 30989.79 | 38472.53 |
| | | Other Operating Income | 31.11 | 32.80 | 16.34 | 92.38 | 05.20 | 120.96 |
| | | Total income from Operations (net) | 14345.82 | 15846.99 | 6795.83 | 43915.70 | 85,28 31075.07 | 129.86 38602.39 |
| | H | Total income from Operations (net) | 14343.02 | 15040.99 | 0793.03 | 43915.70 | 31075.07 | 30002.39 |
| 2 | | Expenses | - | | <u> </u> | | | |
| _ | | Cost of materials consumed | 10780.34 | 12646.36 | 5364.64 | 33926.57 | 22934.43 | 30085.22 |
| | | Purchase of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| | Ť | Changes in inventories of finished goods, work-in- | | | | | | |
| | | progress and stock-in-trade | (1025.98) | (579.76) | (40.10) | (1608.88) | (1037.21) | (2162.43) |
| | | Employee benefits expense | 832.26 | 860.56 | 608.03 | 2480.72 | 1897.81 | 2471.85 |
| | | Depreciation and amortisation expense | 746.82 | 745.51 | 777.97 | 2229.44 | 2164.26 | |
| | _ | Other expenditure | 2049.63 | 2096.30 | 1888.74 | 6369.72 | 5131.45 | 6951.76 |
| | _ | Total Expenses | 13383.07 | 15768.97 | 8599.28 | 43397.57 | 31090.74 | 40237.45 |
| | 7 | <u> </u> | | | | | <u> </u> | |
| 3 | 7 | Profit from Operations before Other Income, finance | | 70.00 | (4000 45) | 540.40 | /45.07 | /400F 00 |
| - | | cost and Exceptional Items (1-2) | 962.75 | 78.02 | (1803.45) | 518.13 | (15.67) | (1635.06) |
| 4 | | Other Income | 0.45 | 0.45 | 0.45 | 1.35 | 1.35 | 1.80 |
| 5 | | Profit from ordinary activities before finance cost and | 963,20 | 78.47 | (1803.00) | 519.48 | (14.32) | (1633.26) |
| 5 | | exceptional items (3+4) | | | (1803.00) | | ` | |
| 6 | | Finance costs | 1538.92 | 1540.99 | 1406.55 | 4533.65 | 4435.79 | 5910.54 |
| 7 | | Profit from ordinary activities after finance costs but | (575.72) | (1462.52) | (3209.55) | (4014.17) | (4450,11) | (7543.80) |
| | | before exceptional items (5-6) | | | <u> </u> | <u> </u> | | |
| 8 | | Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 9 | | Profit (+) / Loss (-) from ordinary activities before tax (7+8) | (575.72) | (1462.52) | (3209.55) | (4014.17) | (4450.11) | (7543.80) |
| | Ħ | | | | | | | |
| 10 | | Tax Expense | 46.47 | (169.68) | (200.17) | 101.09 | (590.59) | (878.73) |
| | \dashv | Net Profit (+)/Loss (-) from ordinary activities after | | | | | | |
| 11 | | tax (9-10) | (622.19) | (1292.84) | (3009.38) | (4115.26) | (3859.52) | (6665.07) |
| 12 | | Extraordinary Item (net of tax expense) | | *** | <u> </u> | | | |
| 13 | | Net Profit (+)/Loss (-) for the period (11-12) | (622.19) | (1292.84) | (3009.38) | (4115.26) | (3859.52) | (6665.07) |
| 14 | | Paid-up equity share capital | 5620.55 | 5255.55 | 4765.55 | 5620,55 | 4765.55 | 4765.55 |
| 14 | | (Face value Rs.10/- Per Share) | 5620.55 | 5235.55 | 4765.55 | 3620.33 | 4765.55 | 4705.55 |
| 15 | | Reserves excluding Revaluation Reserves as per | | | | | | 15355.96 |
| 15 | Ц | balance sheet of previous accounting year | | | | | | 10000.00 |
| | H | Earning per share (before and after extraordinary item | | | | | | |
| 16 | | (Face value of Rs. 10/- each) | | | | | | |
| ,,, | ⊢ | Basic (Weighted) | (1.14) | (2.51) | (7.88) | (7.99) | (10.34) | (16.72) |
| \dashv | | Diluted (Weighted) | (1.14) | (2.40) | (7.56) | (7.99) | | (16.63 |
| | | Cash (Weighted) | 0.31 | (1.39) | (6.55) | (3.47) | (6.13) | |



Y

Head Office: 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030

Ph.: +91-161-2225531-35 Fax: +91-161-2226929, 2608784 email: contact@iolcp.com Website: iolcp.com

Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India

Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.

Ph.: +91-1679 -285285-86, Fax: +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

Segment wise Revenue, Results and Capital Employed, under clause 41 of the Listing Agreement

Rs. in Lacs

| Particulars | | | | | | | |
|--|---------------------|----------------------|-------------|-------------------|------------|------------|--|
| | <u> </u> | Quarter ended | <u> </u> | Nine months ended | | Year Ended | |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited | |
| | 31.12.2015 | 30.09.2015 | 31.12.2014 | 31.12.2015 | 31.12.2014 | 31.03.2015 | |
| 1. Segment Revenue | | | | | | | |
| (Net sale/income) | | | | | | | |
| - Chemicals | 8551.39 | 9785.58 | 3951.54 | 26706.22 | 20324.80 | 24648.58 | |
| - Drugs | 7854.13 | 8478.69 | 4141.87 | 23885.50 | 15948.22 | 21092.56 | |
| - Unallocated | 100.49 | 67.69 | 138.12 | 209.34 | 209.24 | 256.89 | |
| Total | 16506.01 | 18331.96 | 8231.53 | 50801.06 | 36482.26 | 45998.03 | |
| Less : Inter segment revenue | 2160.19 | 2484.97 | 1435.70 | 6885.36 | 5407.19 | 7395.64 | |
| Net sales/income from operations | 14345.82 | 15846.99 | 6795.83 | 43915.70 | 31075.07 | 38602.39 | |
| 2. Segment Results | | | | | | | |
| Profit(+)/(loss)(-) before tax and interest | | | | | - | | |
| from each segment) | (700.00) | (4600.07) | (2010.33) | (4093.87) | (3078.19) | (5045.31) | |
| - Chemicals | (760.88) 1602.79 | (1620.27) 1637.97 | 79.84 | 4425.27 | 2868.15 | 3182.53 | |
| - Drugs | 1602.79 | 1037.81 | 19.04 | 4420.21 | 2000.13 | 3102.50 | |
| Total | 841.91 | 17.70 | (1930.49) | 331.40 | (210.04) | (1862.78) | |
| Less: Interest | 1538.92 | 1540.99 | 1406.55 | 4533.65 | 4435.79 | 5910.54 | |
| | | | | | | | |
| Less: Other un-allocable expenditure net of unallocable income | (121.29) | (60.77) | (127.49) | (188.08) | (195.72) | (229.52) | |
| Total Profit(+)/(loss) (-) before tax & Extraordinary items | (575.72) | (1462.52) | (3209.55) | (4014.17) | (4450.11) | (7543.80) | |
| | | | | | | | |
| 3. Capital Employed | | | | | | | |
| (Segment assets - Segment Liabilities) | 3612.47 | 4273.39 | 7749.65 | 3612.47 | 7749.65 | 8750.54 | |
| - Chemicals | 13735.82 | | 14311.42 | 13735.82 | 14311.42 | 11040.72 | |
| - Drugs - Unallocated | 13735.82 | 12944.42 1038.12 | 1847.93 | 1051.95 | 1847.93 | 967.07 | |
| Total | 18400.24 | 18255.93 | 23909.00 | 18400.24 | 23909.00 | 20758.33 | |
| I Viai | 10700.24 | 10230.33 | 20000.00 | 10-00.24 | 2000.00 | | |

NOTES:

- 1. During the quarter Company has completed its Ibuprofen De-bottlenecking/ Re-engineering project by which the capacity of Ibuprofen plant increased from 6000 TPA to 6200 TPA.
- During the quarter ended 31 December 2015, the Company has allotted 36,50,000 equity shares of Rs.10/- each at a premium of Rs.18/- per share to the
 non promoter, on exercise of the option attached with warrants allotted on 04 July 2014. The paid up capital of the company increased to 5,62,05,502
 equity shares of Rs.10/- each.
- 3. The above results have been reviewed by the Audit & Risk Management Committee and were considered and approved by the Board of the Directors at their meeting held on 30 January 2016.
- 4. Limited review of the above unaudited financial results of the Company in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 has been carried out by the Statutory Auditors of the Company.
- 5. Previous period's figures have been regrouped/ reclassified wherever necessary.

Place: Ludhiana Date: 30 January 2016

By order of the Board For IOL Chemicals and Pharmaceuticals Limited

Vijay Kumar Garg Joint Managing Director DIN: 06510248

Head Office: 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030

Ph.: +91-161-2225531-35 Fax: +91-161-2226929, 2608784 email: contact@iolep.com Website: iolep.com

Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India

Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.

Ph.: +91-1679 -285285-86, Fax: +91-1679-285292

S.C. Vasudeva & Co. CHARTERED ACCOUNTANTS

B-XIX-220, Rani Jhansi Road, Ghumar Mandi, Ludhiana - 141 001 Tel.: 0161-2774527, 9815420555 E-mail: ludhiana@scvasudeva.com

Website: www.scvasudeva.com

INDEPENDENT AUDITOR'S REVIEW REPORT

To
The Board of Directors,
IOL Chemicals and Pharmaceuticals Limited
Ludhiana

Introduction

We have reviewed the accompanying statement of standalone unaudited financial results of IOL Chemicals and Pharmaceuticals Limited (the Company) for the quarter and nine months period ended 31st December, 2015. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

Scope of Review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed any audit and, accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

CERTIFIED TO BE TRUE COPY

For IOL Chemicals and Pharmaceuticals Limited

Kitshan Singla Vice President & Company Secretary

Place: Ludhiana

Date: 30th January, 2016

For S.C. Vasudeva & Co. Chartered Accountants

SRN-000235N

"(Sanjiv Mohan) Partner

M. No. 086066